Enamine, Lundbeck Extend Drug Discovery Pact

Enamine Ltd., a provider of drug discovery services leveraging large collections of building blocks and screening compounds, and H. Lundbeck, a global pharmaceutical company researching new drugs for the treatment of central nervous system disorders, have expanded their research collaboration. Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs.
 
Lundbeck has access to: a library of 100,000 new screening compounds for hit finding activities on numerous therapeutic targets; make-on-demand REAL compounds (Nature, 2019, Vol. 566, p. 224–229) for access to billions of novel chemical compounds; and an increased team of Enamine FTE chemists to support all hit related follow-up activities.
 
Dr. Paul Kilburn, director and head of Medicinal Chemistry at Lundbeck said, "Enamine’s REAL Database is allowing us to expedite our hit explosion programs at unmatched speed and synthesis success. We look forward to the results of our HTS campaigns and to continue receiving highly valuable compounds exclusively synthesized for us."
 
Michael Bossert, head of Strategic Alliances at Enamine, said, "We are delighted to extend our collaboration with Lundbeck, with whom we have a strong historical relationship. This reflects the high-performance level already achieved and a confidence mutually shared, which is most gratifying."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.